SMA注射剂市场按作用机制、给药途径、适应症和最终用户划分，全球预测（2026-2032年）

预计到 2025 年，脊髓性肌肉萎缩症 (SMA) 注射剂市值将达到 45.8 亿美元，到 2026 年将成长至 51 亿美元，到 2032 年将达到 112.4 亿美元，复合年增长率为 13.67%。

主要市场统计数据
基准年 2025	45.8亿美元
预计年份：2026年	51亿美元
预测年份：2032年	112.4亿美元
复合年增长率 (%)	13.67%

为脊髓性肌肉萎缩症（SMA）注射疗法建立清晰的策略框架，阐明影响该疗法的临床、物流和相关人员动态，为决策者提供背景资讯。

脊髓性肌肉萎缩症（SMA）曾是一种几乎必然致命的儿童疾病，如今已发展成为一个复杂的治疗领域，其特点是技术的飞速发展、精细的临床管理以及不断演进的患者照护模式。注射型疾病修正治疗的出现重塑了临床实践，要求临床医生、支付方、生产商和看护者适应新的给药通讯协定、安全监测框架和长期疗效追踪。过去十年，治疗方法创新已将讨论的重点从主要针对症状的缓解治疗转向旨在改变疾病本身生物学机制的干预措施，而这种演变也带来了一系列独特的运营、监管和市场进入挑战。

分子方法、给药方式和医疗保健系统重塑的进步如何融合，正在重塑注射型脊髓性肌肉萎缩症（SMA）治疗给药模式的未来？

分子生物学、递送技术和医疗保健系统组织的进步正在改变注射型脊髓性肌肉萎缩症（SMA）的治疗格局。基因为基础的介入和反义寡核苷酸疗法已日趋成熟，如今，作用机制的比较主要主导患者特征、给药物流和长期安全性监测要求。因此，治疗路径正在进行重组，以支持早期诊断、协调的多学科管理以及长期功能和生活品质结果的计划性随访。

评估2010年代中期贸易政策调适对注射SMA治疗相关的供应链结构、筹资策略和製造地决策的影响

贸易和关税政策的变化会波及到支持脊髓性肌肉萎缩症（SMA）注射疗法的专业供应链，影响原料采购、生产投入和跨境物流的成本效益。 2025年，美国关税调整和国际报復行动引发了关于最终灌装和包装流程位置、关键试剂筹资策略以及长期供应协议建构等方面的新考量。拥有垂直整合生产流程的企业和拥有多元化供应商网路的企业，由于对载体、脂质体和特殊辅料等进口成分的依赖程度不同，其营运受到的影响也各不相同。

对注射型 SMA 治疗进行全面的細項分析，将作用机制、给药途径、临床亚型、临床环境和分销管道与营运和策略重点联繫起来。

这种细分方法为解读注射型脊髓性肌肉萎缩症（SMA）治疗的临床和商业性趋势提供了一个系统性的观点，它能够识别作用机制、给药途径、临床适应症、临床环境和分销管道等方面的差异。作用机制分析比较了反义寡核苷酸疗法和基因疗法，评估了不同的生物疗法如何影响给药间隔、安全监测需求和长期照护。从给药途径的角度来看，鞘内注射和静脉注射之间的差异揭示了不同的基础设施需求、临床医生技能要求以及患者准备情况，这些都会显着影响治疗的普及和护理流程。

区域策略资讯：分析管理体制、医疗体係成熟度和基础设施的差异如何影响注射用脊髓性肌肉萎缩症（SMA）治疗药物的供应和取得。

受法规结构、医疗体系组织结构和当地临床能力的影响，区域趋势为注射型脊髓性肌肉萎缩症（SMA）治疗药物的引入创造了不同的运作环境。在美洲地区，临床生态系统的特点是拥有先进的诊断网络、成熟的卓越中心以及优先考虑持续临床获益证据的支付方结构。这些因素支持复杂治疗模式的快速应用，同时加强对真实世界疗效的监测。整合式医疗协调和与支付方谈判的需求尤其突出，相关人员通常致力于证明疗效随时间推移而改善，以确保医保覆盖并扩大患者群体。

在那些将先进的治疗方法知识、生产韧性和真实世界证据能力相结合，以支持可持续采用和获取的组织中，出现了一种清晰的战略优势模式。

SMA注射剂生态系统中的领导者展现出一致的能力模式，并将其转化为竞争优势：深厚的先进技术专长、整合的临床开发管道以及灵活的生产策略。持续投资于载体和寡核苷酸平台技术并配备完善的药物监测系统的公司，更有能力应对复杂的监管要求，并产生支付方日益重视的长期安全性数据。从学术合作到契约製造联盟等策略伙伴关係，能够拓展企业能力并加速临床转化。同时，优先参与专科药局网路和卓越中心专案的公司，通常能够更顺利地完成产品上市。

实际可行、优先排序的策略性倡议，整合临床、营运和商业能力，以加速注射型脊髓性肌肉萎缩症（SMA）治疗药物的普及并确保其可持续供应。

产业领导者应优先考虑整合临床开发、营运准备和支付方参与，以确保患者能够持续获得注射型脊髓性肌肉萎缩症（SMA）治疗。首先，将真实世界证据收集纳入核准后计画和註册登记，将增强药物的价值提案，支持按绩效付费的合约模式，同时也有助于制定安全监测通讯协定和长期照护计画。其次，扩大临床医生培训计画并对给药中心进行认证，将减少操作差异，改善患者体验，尤其对于需要专业知识的鞘内给药。第三，投资于分散式生产和二级供应商认证，将降低政策和关税风险，缩短前置作业时间，并保障区域供应的连续性。

采用透明的混合方法研究策略，结合对关键相关人员的访谈、监管和临床文献综述以及同行检验，以获得可操作的见解。

本研究综合分析采用混合方法，将质性研究的初步发现与对临床、监管和营运资讯来源的严格审查相结合。一级资讯来源包括对经验丰富的鞘内和静脉注射医生、供应链主管、专科药房运营人员以及患者权益相关人员的结构化访谈，以提供关于治疗路径、培训需求和分销挑战的实地观点。次要研究包括对同侪审查的临床研究、监管指导文件、临床试验註册库和报销政策公告进行系统性审查，以验证有关安全性、给药通讯协定和支付方期望的证据。

简要概述强调了临床、生产和支付方等各相关人员之间密切合作的必要性，以实现注射型SMA治疗给患者带来的持续获益。

注射型SMA治疗领域正处于转折点，科学进步、给药创新和系统层面的准备将共同决定患者的用药机会和长期治疗效果。有效的策略需要同步进行证据生成，并兼顾临床专案设计、生产规模化、分销管道的韧性以及与支付方的协调。能够认识到特定机制的临床需求、给药途径的物流以及医疗环境物流情况之间相互依存关係的相关人员，将更有能力将治疗潜力转化为切实的患者获益。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依作用机转分類的SMA注射剂市场

• 反义寡核苷酸疗法
• 基因治疗

9. 按给药途径分類的SMA注射剂市场

• 鞘内注射
• 静脉注射

第十章 依适应症分類的SMA注射剂市场

• 一型
• II 型
• III型
• 四型

第十一章 以最终用户分類的SMA注射剂市场

• 诊所
  • 门诊部
  • 专科诊所
• 居家医疗
• 医院
  • 私立医院
  • 公立医院

12. 按地区分類的SMA注射剂市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 按组别分類的SMA注射剂市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国SMA注射剂市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

15. 美国脊髓性肌肉萎缩症注射市场

第十六章：中国SMA注射剂市场

第十七章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Astellas Pharma Inc.
• Audentes Therapeutics, Inc.
• Audentes Therapeutics, Inc.
• Biogen Inc.
• Biohaven Pharmaceutical Holding Company Ltd.
• BridgeBio Pharma, Inc.
• Catalyst Pharmaceuticals, Inc.
• Cytokinetics, Inc.
• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• Ionis Pharmaceuticals, Inc.
• NMD Pharma A/S
• Novartis AG
• Novartis Gene Therapies, Inc.
• Pfizer Inc.
• PTC Therapeutics, Inc.
• Regenxbio Inc.
• Sarepta Therapeutics, Inc.
• Scholar Rock, Inc.
• Shionogi & Co., Ltd.

The Injections for SMA Market was valued at USD 4.58 billion in 2025 and is projected to grow to USD 5.10 billion in 2026, with a CAGR of 13.67%, reaching USD 11.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 4.58 billion
Estimated Year [2026]	USD 5.10 billion
Forecast Year [2032]	USD 11.24 billion
CAGR (%)	13.67%

A clear strategic framing of the clinical, logistical, and stakeholder dynamics shaping injection-based therapies for spinal muscular atrophy that set the context for decision-makers

Spinal muscular atrophy (SMA) has transformed from a uniformly fatal pediatric condition into a complex therapeutic area defined by rapid technological advances, nuanced clinical management, and evolving patient care paradigms. The emergence of injection-based disease-modifying therapies has reoriented clinical practice, requiring clinicians, payers, manufacturers, and caregivers to adapt to new administration protocols, safety monitoring frameworks, and long-term outcome tracking. Over the last decade, therapeutic innovation has shifted conversations from primarily symptomatic care toward interventions designed to alter disease biology, and this evolution has created a distinct set of operational, regulatory, and market-access challenges.

This introduction frames the injectable therapeutics landscape by mapping the interplay between clinical evidence generation, route-of-administration logistics, and stakeholder decision-making. It highlights the necessity of integrating clinical program design with manufacturing scalability and distribution resilience. The content underscores how patient-centric care models and multidisciplinary treatment teams are becoming central to effective deployment of intrathecal and intravenous therapies. Ultimately, this section positions readers to understand subsequent analyses by clarifying the medical, logistical, and strategic variables that define successful commercialization and sustained patient benefit in SMA injection therapies.

How converging advances in molecular approaches, delivery methods, and health-system redesign are reshaping the future of injectable SMA treatment delivery models

The injectable SMA landscape is undergoing transformative shifts driven by convergent advances in molecular biology, delivery technologies, and health-system organization. Gene-based interventions and antisense oligonucleotide approaches have matured to the point where comparative decision-making between mechanisms of action is dominated by patient characteristics, dosing logistics, and long-term safety monitoring requirements. As a result, care pathways are being reconfigured to support earlier diagnosis, coordinated multidisciplinary management, and programmatic follow-up that captures functional and quality-of-life outcomes over time.

Concurrently, delivery innovations are influencing where and how treatments are administered. Intrathecal delivery protocols have prompted investments in specialized clinical infrastructure and clinician training, while intravenous administration modalities are prompting consideration of infusion centers and homecare readiness. Payers and health systems are responding to outcomes-based evidence demands by emphasizing real-world evidence collection and registries. Furthermore, supply-chain resilience and manufacturing footprint are now strategic differentiators as stakeholders assess the ability to deliver consistent therapy access across geographies. Together, these shifts are reshaping clinical trial design, regulatory engagement, and commercialization tactics, compelling a systems-level approach to bringing injectable SMA therapies to patients.

Assessment of how mid-decade trade policy adjustments influenced supply-chain architecture, sourcing strategies, and manufacturing footprint decisions relevant to injectable SMA therapies

Policy changes in trade and tariff regimes have the potential to ripple through the specialized supply chains that support injectable therapies for SMA, affecting raw material sourcing, manufacturing inputs, and the cost-efficiency of cross-border logistics. In 2025, tariff adjustments in the United States and reciprocal measures internationally introduced new considerations around the location of final fill-finish operations, procurement strategies for critical reagents, and the structuring of long-term supplier agreements. Organizations with vertically integrated manufacturing and those that have diversified supplier networks experienced differing operational impacts depending on their dependence on imported components for vectors, lipids, and specialty excipients.

In response, companies accelerated strategies to mitigate tariff-driven risk by increasing local content where feasible, negotiating longer-term supply contracts, and accelerating qualification of secondary suppliers. These adaptations also incentivized investment in regional manufacturing capacity and cold-chain redundancies to preserve continuity of care. Payers and providers likewise began to re-evaluate contracting models to reflect the increased complexity of cross-border supply economics, and some organizations prioritized contractual clauses that allocate tariff risk. While tariffs introduced incremental costs and logistical complexity, their most consequential effect was to catalyze strategic shifts in sourcing and manufacturing footprints, prompting stakeholders to place greater emphasis on supply security and to redesign procurement governance frameworks.

Comprehensive segmentation insights that link mechanism, administration route, clinical subtype, care setting, and distribution pathway to operational and strategic priorities for injectable SMA therapies

Segmentation provides a structured lens through which to interpret clinical and commercial dynamics in injectable SMA therapies, acknowledging variation across mechanism of action, administration route, clinical indication, care setting, and distribution pathway. Analysis by mechanism of action contrasts Antisense Oligonucleotide Therapy with Gene Therapy, evaluating how differing biological modalities shape dosing cadence, safety-monitoring requirements, and long-term care implications. When viewed through the prism of route of administration, distinctions between Intrathecal Injection and Intravenous Injection reveal diverging infrastructure demands, clinician skill requirements, and patient suitability considerations that materially affect treatment adoption and care workflows.

Indication-based segmentation across Type I, Type II, Type III, and Type IV captures the heterogeneity of disease onset and progression, which in turn influences timing of intervention, expected clinical outcomes, and registrational evidence strategies. Examining end-user environments clarifies operational readiness by partitioning Clinics, Homecare Settings, and Hospitals, with Clinics further segmented into Ambulatory Clinics and Specialty Clinics, and Hospitals differentiated between Private Hospitals and Public Hospitals; this reveals where investments in training, monitoring, and infusion capacity are most needed. Distribution channel segmentation distinguishes Hospital Pharmacy, Retail Pharmacy, and Specialty Pharmacy, with Hospital Pharmacy subdivided into Contract Pharmacy and In-House Pharmacy, and Retail Pharmacy categorized as Chain Pharmacy, Independent Pharmacy, and Online Pharmacy; these distinctions highlight how channel selection affects cold-chain responsibilities, patient access, and reimbursement interactions. Together, these segmentation axes enable decision-makers to tailor clinical development, commercialization, and operational plans to the nuanced needs of each patient cohort and care environment.

Regional strategic intelligence highlighting how differences in regulatory regimes, health-system maturity, and infrastructure shape delivery and access for injectable SMA therapies

Regional dynamics create distinct operational environments for deploying injectable SMA therapies, influenced by regulatory frameworks, health-system organization, and local clinical capacity. In the Americas, the clinical ecosystem is characterized by advanced diagnostic networks, established centers of excellence, and payer structures that prioritize evidence of sustained clinical benefit; these factors support rapid adoption of complex delivery models but also place heightened scrutiny on real-world outcomes. The necessity for integrated care coordination and payer negotiations is particularly pronounced, and stakeholders often focus on demonstrating longitudinal functional improvements to secure coverage and broaden access.

Europe, Middle East & Africa present a mosaic of regulatory approaches, reimbursement mechanisms, and clinical infrastructure maturity. In several European health systems, centralized HTA processes and national procurement strategies shape access timelines and post-market evidence commitments, while regions with constrained specialist resources may require innovative administration models and capacity-building initiatives. The Middle East and Africa exhibit variability in specialist availability and cold-chain infrastructure, prompting targeted investments in regional centers and training to enable equitable access. In Asia-Pacific, the landscape is driven by rapid adoption in markets with established biotech manufacturing and by emerging markets that prioritize cost-effective distribution models; here, strategic partnerships with regional manufacturers and adaptive pricing schemes often determine the pace at which newer therapies enter routine care. Awareness of these regional distinctions guides prioritization of clinical site selection, manufacturing localization, and tailored market-access strategies to ensure therapies reach appropriate patient populations efficiently.

Clear patterns of strategic advantage among organizations that align advanced modality expertise, manufacturing resilience, and real-world evidence capabilities to support sustainable launch and access

Leading organizations in the injectable SMA ecosystem demonstrate a consistent pattern of capabilities that translate into competitive advantage: deep expertise in advanced modalities, integrated clinical development pathways, and flexible manufacturing strategies. Companies that combine sustained investment in vector and oligonucleotide platform technology with robust pharmacovigilance systems are better positioned to navigate complex regulatory expectations and to generate the long-term safety data that payers increasingly require. Strategic partnerships-ranging from academic collaborations to contract manufacturing alliances-amplify capacity and accelerate clinical translation, while companies with early commitments to specialty pharmacy networks and center-of-excellence programs typically achieve smoother launches.

The ability to operationalize training programs for intrathecal administration, to scale cold-chain distribution, and to support homecare or clinic-based infusion alternatives separates organizations that can deliver at scale from those that face bottlenecks. Moreover, firms that proactively invest in real-world evidence generation, patient registries, and outcomes-based contracting frameworks cultivate stronger dialogues with payers and providers. Finally, nimble commercialization models that integrate field-based clinician education with digital patient-support services enhance adherence and retention in long-term follow-up programs, creating a virtuous circle of improved clinical outcomes and stronger value demonstration.

Practical and prioritized strategic moves that align clinical, operational, and commercial capabilities to accelerate access and ensure sustainable delivery of injectable SMA therapies

Industry leaders should prioritize an integrated approach that aligns clinical development with operational readiness and payer engagement to ensure durable access to injectable SMA therapies. First, embedding real-world evidence collection into post-approval programs and registries will strengthen value propositions and support outcome-based contracting, while also informing safety-monitoring protocols and long-term care planning. Second, expanding clinician training programs and certifying administration centers will reduce procedural variability and improve patient experience, especially for intrathecal administration which requires specialized expertise. Third, investing in distributed manufacturing and secondary supplier qualification can mitigate policy and tariff risk, shorten lead times, and support regional supply continuity.

Commercial strategies should include segmentation-aligned channel planning that recognizes differing logistics needs across hospital pharmacies, retail pharmacies, and specialty distribution partners, while simultaneously optimizing patient support programs to address adherence and infusion-site preferences. Collaborations with payers to design risk-sharing or milestone-based reimbursement models can lower barriers to access and align incentives around measurable patient outcomes. Finally, pursuing strategic partnerships for homecare infusion capabilities and telehealth-enabled follow-up will enhance care continuity for patients in dispersed geographies. These recommendations provide a pragmatic roadmap to translate clinical innovation into accessible, sustainable care pathways for patients living with SMA.

Transparent mixed-methods research approach combining primary stakeholder interviews, regulatory and clinical literature review, and expert validation to support actionable insights

This research synthesis is grounded in a mixed-methods approach that integrates primary qualitative insights with a rigorous review of clinical, regulatory, and operational sources. Primary inputs included structured interviews with clinicians experienced in intrathecal and intravenous administration, supply-chain executives, specialty pharmacy operators, and patient advocacy stakeholders, providing frontline perspectives on care pathways, training needs, and distribution challenges. Secondary research comprised a systematic review of peer-reviewed clinical studies, regulatory guidance documents, clinical trial registries, and reimbursement policy announcements to triangulate evidence on safety profiles, administration protocols, and payer expectations.

Data synthesis employed thematic coding of qualitative interviews to identify recurring operational constraints and strategic enablers, while documentary analysis informed comparative assessment of regional regulatory environments and distribution models. Where appropriate, findings were validated through expert panel review that included clinical and manufacturing specialists to ensure practical relevance. This methodology prioritizes transparency and reproducibility: core assumptions, source lists, and interview frameworks are documented in the methodological appendix, enabling readers to assess the robustness of the conclusions and to adapt the approach for internal decision-making processes.

A concise synthesis underscoring the necessity of cross-stakeholder alignment across clinical, manufacturing, and payer domains to realize sustained patient benefit from injectable SMA therapies

The injectable SMA therapeutic arena stands at an inflection point where scientific progress, delivery innovation, and system-level preparedness collectively determine patient access and long-term outcomes. Effective strategies require synchronizing clinical program design with manufacturing scale-up, distribution resilience, and payer-aligned evidence generation. Stakeholders that recognize the interdependencies between mechanism-specific clinical requirements, route-of-administration logistics, and care-environment readiness will be better equipped to translate therapeutic potential into meaningful patient benefit.

Moving forward, success will favor organizations that adopt proactive supply-chain strategies, invest in clinician training and center certification, and rigorously pursue real-world evidence that informs reimbursement conversations. By focusing on these domains, industry participants can strengthen the continuum from discovery to everyday clinical practice, ensuring that advances in antisense oligonucleotide therapies and gene therapies are realized as durable improvements in patient function and quality of life. The path ahead requires collaboration across payers, providers, manufacturers, and patient groups to build resilient systems that deliver innovative injectable therapies to those who need them most.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Injections for SMA Market, by Mechanism Of Action

• 8.1. Antisense Oligonucleotide Therapy
• 8.2. Gene Therapy

9. Injections for SMA Market, by Route Of Administration

• 9.1. Intrathecal Injection
• 9.2. Intravenous Injection

10. Injections for SMA Market, by Indication

• 10.1. Type I
• 10.2. Type II
• 10.3. Type III
• 10.4. Type IV

11. Injections for SMA Market, by End User

• 11.1. Clinics
  • 11.1.1. Ambulatory Clinics
  • 11.1.2. Specialty Clinics
• 11.2. Homecare Settings
• 11.3. Hospitals
  • 11.3.1. Private Hospitals
  • 11.3.2. Public Hospitals

12. Injections for SMA Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Injections for SMA Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Injections for SMA Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Injections for SMA Market

16. China Injections for SMA Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Astellas Pharma Inc.
• 17.6. Audentes Therapeutics, Inc.
• 17.7. Audentes Therapeutics, Inc.
• 17.8. Biogen Inc.
• 17.9. Biohaven Pharmaceutical Holding Company Ltd.
• 17.10. BridgeBio Pharma, Inc.
• 17.11. Catalyst Pharmaceuticals, Inc.
• 17.12. Cytokinetics, Inc.
• 17.13. F. Hoffmann-La Roche Ltd.
• 17.14. Genentech, Inc.
• 17.15. Ionis Pharmaceuticals, Inc.
• 17.16. NMD Pharma A/S
• 17.17. Novartis AG
• 17.18. Novartis Gene Therapies, Inc.
• 17.19. Pfizer Inc.
• 17.20. PTC Therapeutics, Inc.
• 17.21. Regenxbio Inc.
• 17.22. Sarepta Therapeutics, Inc.
• 17.23. Scholar Rock, Inc.
• 17.24. Shionogi & Co., Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL INJECTIONS FOR SMA MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL INJECTIONS FOR SMA MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRATHECAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRATHECAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRATHECAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE I, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE I, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE II, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE II, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE III, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE III, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE III, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE IV, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE IV, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE IV, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY AMBULATORY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY AMBULATORY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY AMBULATORY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 55. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 56. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 57. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 58. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 59. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 60. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 61. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 63. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 64. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 65. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 66. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 67. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 68. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 70. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 71. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 72. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 73. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 74. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 75. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 82. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 83. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 84. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 85. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 86. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 87. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 88. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 89. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 90. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 91. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 92. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 93. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 94. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 95. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 96. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 97. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 98. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 99. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 100. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 101. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 102. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 103. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 104. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 105. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 106. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 107. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 108. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 109. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 111. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 113. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 114. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 115. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 116. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 117. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 118. GCC INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 119. GCC INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 120. GCC INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 121. GCC INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 122. GCC INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 123. GCC INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 124. GCC INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 125. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 126. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 127. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 128. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 129. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 130. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 131. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 132. BRICS INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 133. BRICS INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 134. BRICS INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 135. BRICS INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 136. BRICS INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 137. BRICS INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 138. BRICS INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 139. G7 INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 140. G7 INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 141. G7 INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 142. G7 INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 143. G7 INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 144. G7 INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 145. G7 INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 146. NATO INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 147. NATO INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 148. NATO INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 149. NATO INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 150. NATO INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 151. NATO INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 152. NATO INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 153. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 154. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 155. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 156. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 157. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 158. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 159. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 160. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 161. CHINA INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 162. CHINA INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 163. CHINA INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 164. CHINA INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 165. CHINA INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 166. CHINA INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
• TABLE 167. CHINA INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)